CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 10,750	$ 13,979
Marketable debt securities	2,478	2,987
Receivables	9,054	9,369
Inventories	2,142	2,095
Other current assets	5,762	4,832
Total Current Assets	30,186	33,262
Property, plant and equipment	5,970	6,049
Goodwill	20,446	20,502
Other intangible assets	37,690	42,527
Deferred income taxes	1,337	1,439
Other non-current assets	4,728	5,535
Total Assets	100,357	109,314
Current Liabilities:
Short-term debt obligations	4,953	4,948
Accounts payable	2,882	2,949
Other current liabilities	13,080	13,971
Total Current Liabilities	20,915	21,868
Deferred income taxes	3,034	4,501
Long-term debt	37,107	39,605
Other non-current liabilities	6,640	7,334
Total Liabilities	67,696	73,308
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	44,375	44,361
Accumulated other comprehensive loss	(992)	(1,268)
Retained earnings	24,217	23,820
Less cost of treasury stock	(35,292)	(31,259)
Total Bristol-Myers Squibb Company Shareholders’ Equity	32,600	35,946
Noncontrolling interest	61	60
Total Equity	32,661	36,006
Total Liabilities and Equity	$ 100,357	$ 109,314